.
Thursday 26th June 2025
Cavendish Conference Centre
.
This website is intended for healthcare professionals
Thursday 26th June 2025
Cavendish Conference Centre
.
Please note: The sponsors did not provide any input or control over the agenda, content creation, or speaker selection, except for their sponsored sessions.
Novo Nordisk has provided sponsorship to MA Healthcare to cover the cost of a stand space for this meeting. Novo Nordisk has had no influence over the meeting agenda or arrangements except where indicated.
AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca
has had no editorial input into or control over the agenda, content development or choice of
speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia.
Diabetes is a disease of complications, particularly cardiovascular disease. In this session, we discuss, in simple terms and using a case study based approach, how to recognise and reduce CVD risk in people living with diabetes. The session will include an overview of making choices about which medication to use, how to address raised blood pressure and what to do about lipids.
This promotional meeting has been organised and funded by Novo Nordisk and is intended for
GB healthcare professionals only. Novo Nordisk products will be discussed at this meeting.
This is a promotional symposium sponsored and organised by AstraZeneca and is
intended for UK HCPs only.
Diabetic foot disease is complex and requires a multidisciplinary approach to management that focuses on early detection and prevention. Regular foot screening and assessment play a pivotal role in the early identification of any foot health changes and can prevent complications such as ulceration, infection, gangrene, and amputation. Timely access to foot health teams optimises outcomes, significantly improves quality of life, making it a central focus in diabetic footcare pathways.
Diabetes mellitus (DM) is the leading cause of preventable sight loss in adults of working age in the UK. People with DM are at increased risk of developing, cataracts, glaucoma diabetic retinopathy and maculopathy. Early detection of diabetes, managing diabetes well and avoiding damage caused by hyperglycaemia and screening programmes can reduce the risk of sight loss in people with diabetes. This presentation explains how diabetes increases the risk of visual problems, how risks can be reduced and how problems can be treated.
Helping our patients with lifestyle change can be confusing - what is effective, what isn’t? How impactful can lifestyle change be? How does it compare to medical management? In this session we will cover
-how to use lifestyle change to optimise outcomes vs numbers
-how our lifestyles impact our epigenome, chronic inflammation and microbiome to impact health outcomes
-what are the highest impact lifestyle shifts, and how to fit these into your brief patient interaction.